Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
32 pending office actions • 19 art units • 28 examiners • 0 of 32 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
AbbVie Inc. has 34 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 30 distinct examiners and 20 distinct art units, showing broad examiner coverage with some technical-unit repetition.
RICCI, CRAIG D is the busiest examiner, with 3 pending matters. The limited concentration makes broad docket coordination more important than a strategy focused on one examiner. Counsel can use the art-unit groupings to organize related technical and prior-art analysis.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (12%) |
| §103 only | 6 (19%) |
| §112 only | 3 (9%) |
| Double-patenting only | 2 (6%) |
| Double-patenting + other | 5 (16%) |
| Multi-statute (no §101) | 10 (31%) |
| No statute on record | 2 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 3 | 53.7% | +52.6% |
| FREDRICKSON, COURTNEY B | 2 | 75.4% | +29.6% |
| LI, RUIXIANG | 2 | 59.5% | +18.7% |
| JANOSKO, CHASITY PAIGE | 1 | 15.9% | +63.6% |
| PATEL, AREN | 1 | 77.6% | +17.2% |
| DOUBRAVA, JOHN A | 1 | 76.8% | +26.6% |
| BASQUILL, SEAN M | 1 | 38.8% | +21.7% |
| CRAIGO, BAHAR ALAWI | 1 | 47.3% | +27.2% |
| AGUIRRE, AMANDA L | 1 | 77.3% | +15.7% |
| DUDDEN, TERESA MARIE | 1 | 48.1% | +45.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18476916 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | RZECZYCKI, PHILLIP MATTHEW | 9d |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | JANOSKO, CHASITY PAIGE | — |
| 18646562 | INJECTION DEVICE | DOUBRAVA, JOHN A | — |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | BASQUILL, SEAN M | — |
| 18890599 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS | SAIDHA, TEKCHAND | — |
| 18809439 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | WILSON, JERICA KATLYNN | — |
| 18753308 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER | FREDRICKSON, COURTNEY B | — |
| 18742823 | BROMODOMAIN INHIBITORS | SHIAO, YIH-HORNG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18015136 | TISSUE EXPANSION DEVICE WITH FLUID COLLECTION | DUDDEN, TERESA MARIE | 4d overdue |
| 17325900 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | RICCI, CRAIG D | 13d |
| 19417018 | SODIUM CHLORITE COMPOSITIONS WITH ENHANCED ANTI-MICROBIAL EFFICACY AND REDUCED TOXICITY | RICCI, CRAIG D | — |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | JANOSKO, CHASITY PAIGE | — |
| 18800556 | INFLATABLE PROSTHESES AND METHODS OF MAKING SAME | PATEL, AREN | — |
| 18646562 | INJECTION DEVICE | DOUBRAVA, JOHN A | — |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | BASQUILL, SEAN M | — |
| 18582331 | DERMAL FILLER COMPOSITIONS | CRAIGO, BAHAR ALAWI | — |
| Art Unit | Apps |
|---|---|
| 3783 | 4 |
| 1611 | 3 |
| 3774 | 3 |
| 1621 | 3 |
| 1623 | 3 |
| 1674 | 2 |
| 1693 | 2 |
| 1613 | 1 |
| 1614 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19417018 | SODIUM CHLORITE COMPOSITIONS WITH ENHANCED ANTI-MICROBIAL EFFICACY AND REDUCED TOXICITY | RICCI, CRAIG D | 1611 | §102DP | Non-Final OA | — | Pending | Dec 11, 2025 |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | JANOSKO, CHASITY PAIGE | 1613 | §103§112 | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18800556 | INFLATABLE PROSTHESES AND METHODS OF MAKING SAME | PATEL, AREN | 3774 | §103 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18646562 | INJECTION DEVICE | DOUBRAVA, JOHN A | 3783 | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18611454 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCESS | BASQUILL, SEAN M | 1614 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18582331 | DERMAL FILLER COMPOSITIONS | CRAIGO, BAHAR ALAWI | 1699 | DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18478718 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDERECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | AGUIRRE, AMANDA L | 1626 | DP | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18015136 | TISSUE EXPANSION DEVICE WITH FLUID COLLECTION | DUDDEN, TERESA MARIE | 3774 | §103 | Non-Final OA | 4d overdue | Pending | Jan 09, 2023 |
| 17515228 | TISSUE EXPANSION DEVICE | MANNAN, MIKAIL A | 3774 | §103 | Non-Final OA | — | Pending | Oct 29, 2021 |
| 19189086 | RISANKIZUMAB COMPOSITIONS | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | — | Pending | Apr 24, 2025 |
| 18890599 | CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONS | SAIDHA, TEKCHAND | 1652 | §102§112 | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18809439 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | WILSON, JERICA KATLYNN | 1621 | §101§103Other | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18753308 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER | FREDRICKSON, COURTNEY B | 3783 | §102§103§112Other | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18742823 | BROMODOMAIN INHIBITORS | SHIAO, YIH-HORNG | 1691 | §101§112DP | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18670261 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | LI, RUIXIANG | 1674 | §101§112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18710958 | METHODS FOR TREATING ANEMIA OF KIDNEY DISEASE | LI, RUIXIANG | 1674 | §102§112DP | Non-Final OA | — | Pending | May 16, 2024 |
| 18661199 | SEALING ARRANGEMENT FOR SYRINGE | SHAH, NILAY J | 3783 | §101§103 | Non-Final OA | — | Pending | May 10, 2024 |
| 18251079 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | RAO, PADMAJA S | 1627 | §102§103§112 | Non-Final OA | — | Pending | Apr 28, 2024 |
| 18627239 | DOSING REGIMENS FOR USE IN PREVENTING RELAPSE OF ACUTE MYELOID LEUKEMIA FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE | GALSTER, SAMUEL LEONARD | 1693 | §103 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18590729 | SELECTIVE REDUCTION OF ANTIBODIES | VAN DRUFF, SYDNEY | 1643 | §102§103 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18686409 | PROCESS OF MAKING APOPTOSIS-INDUCING AGENTS | DOLETSKI, BLAINE G | 1692 | §102§103DP | Non-Final OA | — | Pending | Feb 24, 2024 |
| 18489058 | DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER | FREDRICKSON, COURTNEY B | 3783 | §112 | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18482794 | COCRYSTALS OF UPADACITINIB | CLARK, AMY LYNN | 1628 | §112 | Final Rejection | — | Pending | Oct 06, 2023 |
| 18476916 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | RZECZYCKI, PHILLIP MATTHEW | 1625 | §102§103§112 | Non-Final OA | 9d | Pending | Sep 28, 2023 |
| 18463183 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | O DELL, DAVID K | 1621 | §103DP | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18462918 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | NOLAN, JASON MICHAEL | 1623 | Other | Final Rejection | 118d overdue | Pending | Sep 07, 2023 |
| 18317725 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | RICCI, CRAIG D | 1611 | §103DP | Non-Final OA | — | Pending | May 15, 2023 |
| 17995874 | CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | YOO, SUN JAE | 1621 | §102§112 | Non-Final OA | — | Pending | Oct 10, 2022 |
| 17995798 | METHODS OF TREATING DIABETIC KIDNEY DISEASE | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §102§103 | Final Rejection | — | Pending | Oct 07, 2022 |
| 17807292 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CHENG, KAREN | 1623 | §103 | Final Rejection | 146d overdue | Pending | Jun 16, 2022 |
| 17446807 | PRODRUG MODULATORS OF THE INTEGRATED STRESS PATHWAY | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Non-Final OA | — | Pending | Sep 02, 2021 |
| 17325900 | METHODS OF TREATING HEAVY MENSTRUAL BLEEDING | RICCI, CRAIG D | 1611 | Other | Non-Final OA | 13d | Pending | May 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAbbVie Inc. has 32 pending office actions as of October 2026, spread across 19 art units and 28 examiners.
Craig D Ricci has the most, with 3 of AbbVie Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
